10/19/2010

France's Cellectis has secured iPS Academia Japan's patents for induced pluripotent stem cells, according to a report by Kyodo News. The agreement allows Cellectis to use the cells to create treatments and to test the efficacy of drug candidates.

Full Story:
Google

Related Summaries